

**Kaiser Foundation Health Plan of Washington
Kaiser Foundation Health Plan of Washington Options, Inc.**
Provider Communications, RCR-A3W-04
PO Box 34262, Seattle WA 98124-1262

August 17, 2026

HEMIN (PANHEMATIN) WILL REQUIRE PRIOR AUTHORIZATION APPROVAL

Dear Provider,

Effective November 1, 2026, Hemin (Panhematin) will be added to the list of **non-Medicare** medical benefit drugs requiring prior authorization. **This letter is a notification of the upcoming change in prior authorization approval required before administering this medication in a physician's office.**

Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) require prior authorization for a select group of injectable drugs that may be administered under the medical benefit in a physician's office or by home infusion. These reviews are intended to ensure consistent benefit adjudication as well as appropriate utilization in accordance with the Kaiser Permanente Pharmacy & Therapeutics Committee's evidence-based criteria for coverage.

BRAND NAME	GENERIC NAME	HCPCS
Panhematin	Hemin	J1640

Prior Authorization Criteria for Hemin (Panhematin):

DRUG NAME	COVERAGE CRITERIA
Hemin (Panhematin)	Medical necessity review required

Additional Information

A complete list of office-administered injectable drugs requiring prior authorization can be found on the Kaiser Permanente provider website at <https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/officeinject>.

To request prior authorization review, please use the Referral Request online form (login required) located on the Kaiser Permanente provider website. You can also fax your request to the Review Services department toll-free at 1-888-282-2685.

Thank you for the care you provide for our members, your patients. If you have any questions about this process, please call Review Services at 1-800-289-1363, Monday through Friday, from 8:00 a.m. to 5:00 p.m.

Sincerely,



Ravi Ubriani, MD, Chair
Pharmacy & Therapeutics Committee